Janssen Announces U.S. FDA Approval Of STELARA® (ustekinumab) For The Treatment Of Adolescents With Moderate To Severe Plaque Psoriasis
BioTech Gate,
HORSHAM, Pa., Oct. 13, 2017 /PRNewswire/ -- Janssen Biotech, Inc., announced today that the U.S.
HORSHAM, Pa., Oct. 13, 2017 /PRNewswire/ -- Janssen Biotech, Inc., announced today that the U.S.
Information contained on this page is provided by an independent third-party content provider.
Information contained on this page is provided by an independent third-party content provider.
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
SOURCE Janssen Biotech - Approval of STELARA® for adolescents 12 years or older provides an important new treatment option for…
HORSHAM, Pa., Oct. 13, 2017 /PRNewswire/ -- Janssen Biotech, Inc., announced today that the U.S.